Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Elite control of HIV Infection: implications for vaccines and treatment.

Walker BD.

Top HIV Med. 2007 Aug-Sep;15(4):134-6. Review.

2.

Elucidating the elite: mechanisms of control in HIV-1 infection.

O'Connell KA, Bailey JR, Blankson JN.

Trends Pharmacol Sci. 2009 Dec;30(12):631-7. doi: 10.1016/j.tips.2009.09.005. Review.

PMID:
19837464
3.

Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV.

Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D.

AIDS. 2009 Jun 1;23(9):1163-9. doi: 10.1097/QAD.0b013e32832b44c8.

PMID:
19444075
4.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
5.
6.

Immunizations for HIV-infected adults: indications, timing, and response.

Spach DH.

Top HIV Med. 2006 Dec-2007 Jan;14(5):154-8.

7.

Incorporating novel virologic tests into clinical practice.

Daar ES.

Top HIV Med. 2007 Aug-Sep;15(4):126-9. Review.

8.

Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.

Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, Hoh R, Stramer SL, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG.

J Virol. 2009 Jan;83(1):329-35. doi: 10.1128/JVI.01763-08. Epub 2008 Oct 22.

9.

Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.

Bello G, Velasco-de-Castro CA, Bongertz V, Rodrigues CA, Giacoia-Gripp CB, Pilotto JH, Grinsztejn B, Veloso VG, Morgado MG.

J Med Virol. 2009 Oct;81(10):1681-90. doi: 10.1002/jmv.21565.

PMID:
19697415
10.

Update on cardiovascular complications in HIV infection.

Currier JS.

Top HIV Med. 2009 Jul-Aug;17(3):98-103. Review.

11.

Syphilis and other sexually transmitted diseases in HIV infection.

Marrazzo J.

Top HIV Med. 2007 Feb-Mar;15(1):11-6.

12.

HIV disease progression: immune activation, microbes, and a leaky gut.

Douek D.

Top HIV Med. 2007 Aug-Sep;15(4):114-7. Review.

13.

The challenges of host and viral diversity in HIV vaccine design.

Brander C, Frahm N, Walker BD.

Curr Opin Immunol. 2006 Aug;18(4):430-7. Epub 2006 Jun 13. Review.

PMID:
16777397
14.

Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study.

Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, Ganesan A, Hale B, Crum-Cianflone N, Delmar J, Barthel V, Quinnan G, Agan BK, Dolan MJ; Infectious Disease Clinical Research Program (IDCRP) HIV Working Group.

J Infect Dis. 2009 Dec 1;200(11):1714-23. doi: 10.1086/646609.

PMID:
19852669
15.

Elite HIV controllers: myth or reality?

Saksena NK, Rodes B, Wang B, Soriano V.

AIDS Rev. 2007 Oct-Dec;9(4):195-207. Review.

PMID:
18219363
16.

Elite controllers as a model of functional cure.

Autran B, Descours B, Avettand-Fenoel V, Rouzioux C.

Curr Opin HIV AIDS. 2011 May;6(3):181-7. doi: 10.1097/COH.0b013e328345a328. Review.

PMID:
21460722
17.

Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection.

Rachinger A, Navis M, van Assen S, Groeneveld PH, Schuitemaker H.

Clin Infect Dis. 2008 Dec 1;47(11):e86-9. doi: 10.1086/592978.

PMID:
18947331
18.

Recent efforts in biomedical prevention of HIV.

Landovitz RJ.

Top HIV Med. 2007 Jun-Jul;15(3):99-103.

19.

Non--AIDS-defining malignancies in HIV.

Mitsuyasu RT.

Top HIV Med. 2008 Oct-Nov;16(4):117-21. Review.

20.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217

Supplemental Content

Support Center